If you feel like you're the only OD who can't get RF/IPL treatments off the ground – you're not.

Only 1.5% of routine eye exams ever turn into an advanced dry eye treatment. That's not my number. It's published in the Review of Optometric Business, May 2025.¹

For every 100 exams... one or two patients. That's the average.

And in the Eyes On Eyecare IPL report, only 6% of surveyed owners rated their financial return on the device as "excellent."¹³

So whatever is sitting in your treatment room right now – an OptiLight, an OptiPlus, an InMode Envision, an iPro Elite – the pattern runs the same everywhere.

The patient has the symptoms. You explain what the treatment does. They seem genuinely interested.

Then the price comes up.

"Let me think about it."

And they don't come back.

Here's what I'm going to show you with published data: that line was never about the money. And it was never about your ability to explain your own specialty.

Before you press play

In the next few minutes you'll be able to verify three things yourself. The published figure that reframes this whole problem – printed in your own trade journal, not my pitch deck. Where the patients you've been told to go find actually are. And why the "think about it" stall is a fixable gap in the process, not a verdict on you.

The video walks the numbers. The article below covers the same ground if you'd rather read. The bold lines cover it if you'd rather skim.

Either way – even if we never talk – you'll leave understanding your own numbers better than you do now. That's the point.

The pattern has a number

Across routine exams, about 1.5% convert to advanced dry eye treatment. When a dedicated dry eye visit happens first, conversion climbs to 29.78%.¹

Read that again. Roughly a twenty-fold difference... from one added step.

The Review of Optometric Business called it a systems problem, not a skill problem. Their words, not mine.¹

And that framing matters, because the rep who sold you the device sold you capability. A machine that treats the condition beautifully.

Nobody sold you the step that routes a diagnosed patient toward it. That step doesn't come in the crate. It was never going to.

"I feel like we built a dry eye center, but we don't have a business engine behind it."

That sentence is the whole problem in fourteen words.

So what actually happens in the last five minutes?

Think about everything a patient has to absorb between "you have meibomian gland dysfunction" and a $1,500 cash decision.

What MGD even is. Why their symptoms keep coming back. Why the drops only ever gave temporary relief. Why insurance won't cover the thing that actually works. Why it's worth paying for anyway.

That's not a quick pitch. That's a belief shift.

And the current model asks you to produce it in the closing minutes of an insurance exam... with the price arriving before the understanding does.

They're not saying no. They're saying the only reasonable thing a person can say when the bill shows up before the explanation is finished:

"Let me think about it."

Five minutes was never the right container for this decision. Same doctor. Same treatment. Same pricing. Different container – that's the entire mechanism behind the 1.5%-to-29.78% gap.¹

The patients were never missing

Surveyed ODs estimate about two-thirds of their patients (67.55%) have some form of dry eye. Only around half (46.38%) ever get diagnosed.²

Sit with that gap for a second.

Roughly a third of the dry eye patients in a typical practice are already in the charts... unlabeled.

Run it against an ordinary panel and you're looking at several hundred dry eye patients a year already walking through your door.³

"I know I have plenty of dry eye patients, but they're not saying yes to procedures."

So if you've been told your problem is demand – more ads, more leads, more strangers – the data points the other way.

The patients were never out in the market. They were in your waiting room the whole time.

What's missing is the step that surfaces them, teaches them, and routes them to the chair.

"My patients won't pay out of pocket." The evidence says otherwise – on one condition.

Across 58 randomized trials and roughly 15,000 people, structured education before a treatment decision nearly doubled the rate of patients choosing care that genuinely fit them.⁴

That's Cochrane – the worldwide gold standard for medical evidence. And I'll flag this plainly rather than let you catch it: those trials come from surgical and dental decisions, not dry eye specifically. The pattern is what transfers.

Education doesn't hype anyone into a chair. It converts the motivated and lets the mismatched opt out. Which is exactly what you want from a cash-pay line with your name on the door.

Want the same pattern closer to a cash decision? In one published bariatric program, adding a short educational class before the consult dropped patient indecision from 23% to 1%.⁸

Twenty-three percent "let me think about it"... down to one.

The condition is sequence. Understanding has to arrive before the price does.

A $1,500 treatment mentioned in the last five minutes of an insurance exam runs that sequence backwards. Which is why the stall was never about the money – and never about your closing ability.

It was the order of operations.

Where the last agency actually lost your money

Here's the part nobody in my industry volunteers, so I will: a real share of practices don't have a demand problem at all. The problem is what happens between "interested" and "in the chair."

Optometry's average no-show rate runs about 24.8%.⁵ A quarter of booked appointments... gone after the ad already worked.

Add the calls that ring out. The patients who clicked something once and never heard anything useful again. The leads that arrive knowing nothing about the treatment they supposedly want.

It's entirely possible to buy real interest and watch all of it drain away before anyone sits in a chair.

Your last agency stopped at the lead. A spreadsheet of names and phone numbers, handed to your front desk.

And here's what they don't tell you: when it doesn't work, they blame your staff for not calling fast enough.

Your staff is already wearing five hats. They don't have time to chase internet leads down and sell strangers on a treatment. And they shouldn't have to.

The difference was never more leads. It's what the lead understands before your staff ever talks to them.

What one Saturday actually runs

The honest division of labor: my team does the marketing. You do the medicine. And the system we hand you covers everything in between.

What my team runs: the ad and the spend, written and managed so it only surfaces people whose dry eye is hurting their sleep and daily life. The vetting, screening every lead for symptoms and readiness the same way a SPEED or OSDI questionnaire would. And the education before they arrive – short videos and plain-language material on what MGD is, why drops never gave lasting relief, and how your RF/IPL device helps. The cash-pay question gets handled early, so the price never lands as a shock.

What you run – with the system we hand you: the Saturday session itself. One hour, in your practice, whenever works. You get the complete, tested playbook: the script, the patient worksheets, the checklists, right down to how to present pricing without feeling like a salesperson. Nothing to invent. Plug and play.

And it's a class, not a pitch. Patients arrive already suffering and pull information from you as the authority in the room. That's the entire reason this converts – no marketer can be the doctor. Only you can.

At the end, the patients who want to start simply pay and get booked for treatment. You're teaching, answering questions, and scheduling the ones who say yes. No Tony Robbins charisma required.

Why cash-pay dry eye is worth building – and why now

A cash-pay dry eye patient is worth about three times a vision-plan patient once the write-offs clear – roughly $617 versus $201.⁹

And the practices that build around dry eye? Published case studies show it growing to as much as 75% of practice revenue.¹⁰

Not by seeing more patients. By earning more per patient they already see.

Now look at what's happening to the other side of your P&L. Revenue per routine exam has flatlined around $325–$375.¹¹

Tele-optometry is already in about 77% of practices – and the fastest-growing piece is AI-assisted remote refraction: an exam with no doctor in the room.¹² The big national chains already run it. They call it a "no doctor, open lanes" retail strategy.

Those same chains and private-equity groups are also buying up independent practices outright. Private ownership fell from 51% to 41% in seven years.⁶

So the routine insurance exam – the thing your whole schedule is built around – is exactly the part everyone else is coming for.

The one thing none of them can take is a cash-pay medical specialty built on a doctor patients trust, delivered in person, in your chair. You already own the machine for it.

One more number. Right now, only about 1 in 4 practices has this technology up and running.¹³ In your area, you're probably still one of the few. That won't stay true. The window where you're the obvious local choice is open now.

The honest math – including the number from the ad

A typical workshop books 5–7 cash-pay patients, at a 40–50% conversion of the room – a range that independent break-even modeling treats as realistic, not optimistic.⁷

The ad you clicked mentioned $10–14K per Saturday. I'm deliberately not repeating that here as a promise. What a Saturday is worth in your practice depends entirely on which device you run and what you charge. Some practices land above that range. Some land below it.

So on the numbers call, we run your actual figures – your pricing, your panel, your market. If the math isn't there, I'll tell you plainly and you'll have lost twenty minutes. I'd rather show you a smaller number that holds than a bigger one that doesn't.

Judge it by a Saturday, not a promise

If you've already spent thousands on agencies with guarantees written to protect them... I get it. I don't blame you for being hesitant. I would be too. That's exactly why I don't want you to judge this by a promise.

Your first workshop is free. My team builds the campaign, vets the patients, and educates them before they arrive – then hands you the complete system to run the session. You just cover the ad spend, and it goes straight to the ad platform. Never to us.

Or if you're sitting on a solid list of past leads and patients, we can fill your first workshop from that instead. That version doesn't cost you anything.

Why waive our fees? Because I'd rather show you than tell you. One Saturday with real patients in your real practice says more than anything I could write on this page. No long contract. No retainer. No fine print.

And look... if your treatment calendar is already full, don't book the call. This is for the doctor who knows the patients are out there and can't get them into the chair.

One last thing, because I mean it. Investing in this technology to help people with chronic dry eye was the right instinct. The medicine was never the problem. You shouldn't have to figure out the marketing side alone. That's the part we carry.